Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0403608 (
ureter
)
9,655
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
This study was conducted to determine whether adenosine 5'-triphosphate (ATP) contributes to nociceptor activity induced by
ureter
distension. Multifibre recordings of
ureter
afferents were made using the guinea pig
ureter
preparation perfused in vitro. Distension of the
ureter
resulted in an initial rapid and later maintained increase in afferent nerve discharge. Intraluminal application of ATP (10-1000 microM, 0.1 ml/min for 3 min) or alpha,beta-meATP (10-1000 microM) mimicked these increases in afferent activity. The afferent responses consisted of fast and slow components. Both agonists caused a sensitisation of the afferents to
ureter
distensions. TNP-ATP (30 microm), a P2X3 receptor antagonist, and the non-specific P2 antagonist, PPADS (100 microm), blocked the rapid and reduced the slower response to ATP. The remaining responses were blocked by the selective A1 receptor antagonist, DPCPX. TNP-ATP and PPADS reduced distension-induced afferent activity. The selective ecto-ATPase inhibitor, ARL-67156 (100, 200 microM) and suramin (100, 200 microM), an ecto-
nucleotidase
inhibitor as well as a P2 receptor antagonist, produced an increase in baseline and distension-induced discharge. These results indicate that the
ureter
epithelium may tonically (at rest) as well as phasically (on distension) release ATP, which stimulates afferent terminals by interacting with multiple P2 and P1 receptors.
...
PMID:Activation of ureter nociceptors by exogenous and endogenous ATP in guinea pig. 1555 43